@article{
 title = {Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory},
 type = {article},
 year = {2016},
 keywords = {Chromogranin A,Epidemiology,Neuroendocrine tumors,Prognostic factors,Survival},
 pages = {e133-e140},
 volume = {12},
 publisher = {American Society of Clinical Oncology},
 id = {e374ac2c-c1d8-36e3-96b4-fa817fdff830},
 created = {2021-08-31T15:56:36.751Z},
 file_attached = {true},
 profile_id = {49efd9d1-b84a-3562-b8db-36e64ac7ba81},
 last_modified = {2021-08-31T15:56:54.193Z},
 read = {false},
 starred = {false},
 authored = {true},
 confirmed = {true},
 hidden = {false},
 citation_key = {Malik2016},
 source_type = {article},
 folder_uuids = {4cfcf1ef-e8a1-481b-9768-92f271f79e14,61cd76d5-8771-4789-bd8b-c373e7bef009},
 private_publication = {false},
 abstract = {Aims: Retrospective review of neuroendocrine tumors (NETs) treated within the Australian Capital Territory to describe the local epidemiology and assess prognostic clinicopathological factors. Methods: Patients with histologically proven non-pulmonary low to intermediate grade NETs were identified from our hospital clinical database. Data were analyzed according to epidemiological, clinical and histopathological characteristics. Results: Of the 107 included patients, the most common primary tumor site was jejunum/ileum (32%), followed by rectum (22%) and pancreas (11.2%). In total, 32% had distant metastases at presentation, most commonly in the liver. Most patients were symptomatic at diagnosis, while 22.4% of cases were found incidentally. Second malignancies, in particular of gastrointestinal origin, were diagnosed in 33.6%. Surgical debulking was the most common treatment (59.8%) while 18% had multimodality therapy. With a median follow-up of 25 months from diagnosis, about 78% of patients are still alive. Median time to first relapse was 15 months and the 5-year survival rate was 80% for NETs of jejunum/ileum. Univariate survival analysis revealed tumor location, high Ki67 index, raised plasma chromogranin A, and urine 5-hydroxyindoleacetic acid upon diagnosis to be associated with shorter 5-year survival. Conclusion: The epidemiologic characteristics and long-term outcome in our series are comparable to other reported studies. This analysis presents some important prognostic factors which could be used for risk stratification in patients with NETs.},
 bibtype = {article},
 author = {Malik, Laeeq and Chua, Yu Jo and Butt, Nadeem S. and Yip, Desmond},
 doi = {10.1111/ajco.12121},
 journal = {Asia-Pacific Journal of Clinical Oncology},
 number = {1}
}

{"_id":"uSHHGtTpxBbSMpBpr","bibbaseid":"malik-chua-butt-yip-singleinstitutionalseriesofneuroendocrinetumorsmanagedintheaustraliancapitalterritory-2016","downloads":0,"creationDate":"2017-11-04T12:35:01.481Z","title":"Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory","author_short":["Malik, L.","Chua, Y., J.","Butt, N., S.","Yip, D."],"year":2016,"bibtype":"article","biburl":"https://bibbase.org/service/mendeley/49efd9d1-b84a-3562-b8db-36e64ac7ba81","bibdata":{"title":"Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory","type":"article","year":"2016","keywords":"Chromogranin A,Epidemiology,Neuroendocrine tumors,Prognostic factors,Survival","pages":"e133-e140","volume":"12","publisher":"American Society of Clinical Oncology","id":"e374ac2c-c1d8-36e3-96b4-fa817fdff830","created":"2021-08-31T15:56:36.751Z","file_attached":"true","profile_id":"49efd9d1-b84a-3562-b8db-36e64ac7ba81","last_modified":"2021-08-31T15:56:54.193Z","read":false,"starred":false,"authored":"true","confirmed":"true","hidden":false,"citation_key":"Malik2016","source_type":"article","folder_uuids":"4cfcf1ef-e8a1-481b-9768-92f271f79e14,61cd76d5-8771-4789-bd8b-c373e7bef009","private_publication":false,"abstract":"Aims: Retrospective review of neuroendocrine tumors (NETs) treated within the Australian Capital Territory to describe the local epidemiology and assess prognostic clinicopathological factors. Methods: Patients with histologically proven non-pulmonary low to intermediate grade NETs were identified from our hospital clinical database. Data were analyzed according to epidemiological, clinical and histopathological characteristics. Results: Of the 107 included patients, the most common primary tumor site was jejunum/ileum (32%), followed by rectum (22%) and pancreas (11.2%). In total, 32% had distant metastases at presentation, most commonly in the liver. Most patients were symptomatic at diagnosis, while 22.4% of cases were found incidentally. Second malignancies, in particular of gastrointestinal origin, were diagnosed in 33.6%. Surgical debulking was the most common treatment (59.8%) while 18% had multimodality therapy. With a median follow-up of 25 months from diagnosis, about 78% of patients are still alive. Median time to first relapse was 15 months and the 5-year survival rate was 80% for NETs of jejunum/ileum. Univariate survival analysis revealed tumor location, high Ki67 index, raised plasma chromogranin A, and urine 5-hydroxyindoleacetic acid upon diagnosis to be associated with shorter 5-year survival. Conclusion: The epidemiologic characteristics and long-term outcome in our series are comparable to other reported studies. This analysis presents some important prognostic factors which could be used for risk stratification in patients with NETs.","bibtype":"article","author":"Malik, Laeeq and Chua, Yu Jo and Butt, Nadeem S. and Yip, Desmond","doi":"10.1111/ajco.12121","journal":"Asia-Pacific Journal of Clinical Oncology","number":"1","bibtex":"@article{\n title = {Single institutional series of neuroendocrine tumors managed in the Australian Capital Territory},\n type = {article},\n year = {2016},\n keywords = {Chromogranin A,Epidemiology,Neuroendocrine tumors,Prognostic factors,Survival},\n pages = {e133-e140},\n volume = {12},\n publisher = {American Society of Clinical Oncology},\n id = {e374ac2c-c1d8-36e3-96b4-fa817fdff830},\n created = {2021-08-31T15:56:36.751Z},\n file_attached = {true},\n profile_id = {49efd9d1-b84a-3562-b8db-36e64ac7ba81},\n last_modified = {2021-08-31T15:56:54.193Z},\n read = {false},\n starred = {false},\n authored = {true},\n confirmed = {true},\n hidden = {false},\n citation_key = {Malik2016},\n source_type = {article},\n folder_uuids = {4cfcf1ef-e8a1-481b-9768-92f271f79e14,61cd76d5-8771-4789-bd8b-c373e7bef009},\n private_publication = {false},\n abstract = {Aims: Retrospective review of neuroendocrine tumors (NETs) treated within the Australian Capital Territory to describe the local epidemiology and assess prognostic clinicopathological factors. Methods: Patients with histologically proven non-pulmonary low to intermediate grade NETs were identified from our hospital clinical database. Data were analyzed according to epidemiological, clinical and histopathological characteristics. Results: Of the 107 included patients, the most common primary tumor site was jejunum/ileum (32%), followed by rectum (22%) and pancreas (11.2%). In total, 32% had distant metastases at presentation, most commonly in the liver. Most patients were symptomatic at diagnosis, while 22.4% of cases were found incidentally. Second malignancies, in particular of gastrointestinal origin, were diagnosed in 33.6%. Surgical debulking was the most common treatment (59.8%) while 18% had multimodality therapy. With a median follow-up of 25 months from diagnosis, about 78% of patients are still alive. Median time to first relapse was 15 months and the 5-year survival rate was 80% for NETs of jejunum/ileum. Univariate survival analysis revealed tumor location, high Ki67 index, raised plasma chromogranin A, and urine 5-hydroxyindoleacetic acid upon diagnosis to be associated with shorter 5-year survival. Conclusion: The epidemiologic characteristics and long-term outcome in our series are comparable to other reported studies. This analysis presents some important prognostic factors which could be used for risk stratification in patients with NETs.},\n bibtype = {article},\n author = {Malik, Laeeq and Chua, Yu Jo and Butt, Nadeem S. and Yip, Desmond},\n doi = {10.1111/ajco.12121},\n journal = {Asia-Pacific Journal of Clinical Oncology},\n number = {1}\n}","author_short":["Malik, L.","Chua, Y., J.","Butt, N., S.","Yip, D."],"urls":{"Paper":"https://bibbase.org/service/mendeley/49efd9d1-b84a-3562-b8db-36e64ac7ba81/file/069e2861-7732-535d-5a57-97ee457b5a2b/Malik_et_al___2013___Single_institutional_series_of_neuroendocrine_tumors_managed_in_the_Australian_Capital_Territory.pdf.pdf"},"biburl":"https://bibbase.org/service/mendeley/49efd9d1-b84a-3562-b8db-36e64ac7ba81","bibbaseid":"malik-chua-butt-yip-singleinstitutionalseriesofneuroendocrinetumorsmanagedintheaustraliancapitalterritory-2016","role":"author","keyword":["Chromogranin A","Epidemiology","Neuroendocrine tumors","Prognostic factors","Survival"],"metadata":{"authorlinks":{"butt, n":"https://www.nsbstat.com/resume/"}},"downloads":0},"search_terms":["single","institutional","series","neuroendocrine","tumors","managed","australian","capital","territory","malik","chua","butt","yip"],"keywords":["chromogranin a","epidemiology","neuroendocrine tumors","prognostic factors","survival"],"authorIDs":["59fdb3f5e73315546e00002b","59ff512dd6a16d6d7a000001","5df4c1e155b997de01000048","5e0cd25c6762d1de01000066","5e108bf9bb9e04df0100003a","5e176adf4df69dde010001c4","5e1890cc779abfdf0100008b","5e19679773bf69de0100003b","5e47bbb16c5c7ede01000089","5e63d38178da4fdf01000052","5e68c167ae547ede01000042","9e2Y2wffnDMymuW6L","HHJSHQNA9NsgYuQQi","RkdR9PKTmMfuqbqBa","TMXjAwttZAc8tbC3L","ZxKWPp4jJwDbRfW2u","aKZgwf4Z2pXLfRtNf","mFebwACuYstZZ7pHd","uBktm5eDqAhE5NdWa","yWQDateN69v7SskRH"],"dataSources":["dAJfw83AXweR2io6m","ya2CyA73rpZseyrZ8","JnyAdS67Rhkx3LrTM"]}